Risks of using psilocybin in treatment of treatment-resistant depression
Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek, Jan Karczmarz, Aleksandra Paprocka, Marika Gutowska, Agnieszka Kosińska, Urszula Świrk, Wiktoria Belcarz, Karolina Kalinowska
Journal of Education, Health and Sport March 7, 2025 DOI: 10.12775/JEHS.2025.79.58319 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin Depression |
| Keywords | Treatment resistant depression Safety Psychedelic assisted therapy Adverse effects Psilocybin therapy |
| Key findings | Establishing robust safety parameters for psilocybin administration is essential for its safe integration into clinical practice for treatment-resistant depression. |
Abstract
Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, highlighting the potential impact of psilocybin as a promising therapeutic option. However, to ensure its safe and effective integration into clinical practice, it is essential to establish robust safety parameters for its administration. This paper focuses on addressing the risks associated with psilocybin therapy. We believe this paper can help understand risks as a platform for safety based treatment. Material and Methods A comprehensive literature search was conducted using the PubMed and Google Scholar databases, supplemented by references cited in the initially identified articles. The search focused on studies and reviews addressing the challenges and risks associated with psilocybin use in the treatment of treatment-resistant depression (TRD).